Section: 18. Medicines for endocrine disorders

Calcitriol

The Expert Committee, after evaluation, declines to list the medicine proposed in the application. The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

**Indication**
Disorders of vitamin D metabolism or transport

**INN**
Calcitriol

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
Oral > Solid > capsule: 0.25 µg ; 0.5 µg

**EML status history**
Application rejected in 2023 (TRS 1049)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions

**Wikipedia**
Calcitriol

**DrugBank**
Calcitriol

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee did not recommend inclusion of the vitamin D analogues alfacalcidol and calcitriol on the complementary list of the EML and EMLc, for the proposed indications of hypoparathyroidism, hypophosphataemic rickets, hypocalcaemic vitamin D dependent/resistant rickets, neonatal hypocalcaemia, chronic kidney disease, and other disorders of vitamin D metabolism or transport at this time. While the application included reference to conditional guideline recommendations for the use of vitamin D analogues in chronic kidney disease, hypophosphataemic rickets and hypoparathyroidism, overall, the Committee noted that evidence base was uncertain due to risk of bias, indirectness when assessing patient-important outcomes, inconsistencies, and imprecision. The Committee considered that the limited likelihood of influencing important clinical outcomes was potentially outweighed by the risks associated with the use of alfacalcidol and calcitriol, such as hypercalciuria, decrease in renal function and cardiovascular risk.